Open AccessThe impact of ASCT on patients with newly diagnosed multiple myeloma who receive RVD induction
Author(s) -
Marlise R. Luskin,
Federico Campigotto,
Paul G. Richardson,
John Koreth,
Irène M. Ghobrial,
Robert Schlossman,
Nikhil C. Munshi,
Edwin P. Alyea,
Robert J. Soiffer,
Diane Warren,
Muriel Gan,
Kathleen T. Finn,
Kenneth C. Anderson,
Edie Weller,
Jacob P. Laubach
Publication year - 2013
Publication title -
journal of hematological malignancies
Language(s) - English
Resource type - Journals
eISSN - 1925-4032
pISSN - 1925-4024
DOI - 10.5430/jhm.v3n1p41
Subject(s) - medicine , autologous stem cell transplantation , lenalidomide , melphalan , multiple myeloma , bortezomib , oncology , induction therapy , dexamethasone , induction chemotherapy , hematopoietic stem cell transplantation , surgery , overall survival , transplantation , chemotherapy